Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||endometrial carcinoma||not applicable||CC-90010||Case Reports/Case Series||Actionable||In a Phase I trial, CC-90010 treatment demonstrated safety, and resulted in a partial response in an endometrial carcinoma patient harboring an ESR1-AKAP12 fusion, ESR1 amplification, and PIK3CA and FGFR2 mutations (PMID: 32240793; NCT03220347).||32240793|